Reports
Reports
Increase in incidence of gynecological disorders is driving the gynecology drugs market size. Gynecology drugs treat cancers of the reproductive system, cramping, pre-menstrual syndrome, and menstrual disorders such as menorrhagia.
Rise in awareness about the advantages of non-hormonal therapy is translating into extensive research being conducted in the gynecology drugs market scenario.
Manufacturers are exploring the incorporation of intrauterine devices that can exercise effective control over postpartum hemorrhage.
They are also looking toward the production of PARP inhibitors, which have been approved by the U.S. Food and Drug Administration for the treatment of gynecological cancers.
Gynecology drugs, also known as reproductive health drugs, imply medications for illnesses that affect the reproductive system, thereby enclosing care for women during as well as after pregnancy. Such drugs treat numerous gynecological diseases that are likely to impact ovaries, uterus, and appendages.
Primary therapeutic categories are inclusive of non-hormonal and hormonal therapy. Hormonal therapy implies treatments adding, blocking, or removing hormones to impede the growth of cancer cells, whereas non-hormonal therapy involves the usage of anti-inflammatory and anti-infective agents, moisturizers, lubricants, and antidepressants.
Apart from treating gynecological cancers, gynecology drugs act as menstrual disorders medications, hormonal gynecological treatments, fertility-enhancing pharmaceuticals, and pregnancy-related medications as well.
However, high cost of hormonal therapies is expected to restrain the gynecology drugs market growth during the forecast period. As per the National Institutes of Health, the lifetime price of hormone therapy with tamoxifen, AI, and switch therapy was US$ 17,759, US$ 15,766, and US$ 15,464, respectively in 2021.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Common symptoms of gynecological diseases include strange vaginal dying, vaginal release, vaginal tingling, pelvic agony, and bosom torment and protuberances.
If left untreated, these diseases may culminate into abnormal vaginal bleeding, burning sensation during urination, bleeding post-menopause, lumps or sores in the genital area, and increased vaginal discharge.
Developing economies are witnessing a higher percentage of women at risk of these ailments as compared to the developed economies, as menstrual hygiene is still a taboo topic in these countries.
Reluctance to discuss these problems openly forces these women to bear the torture solitarily, thereby resulting in the above-mentioned aftereffects. Awareness campaigns are expected to provide respite to the women suffering from these symptoms.
According to the World Health Organization, over 570,000 women worldwide suffer from cervical cancer with 311,000 women succumbing to it.
However, healthcare personnel state that cervical cancer is a successfully treatable form of cancer, only if it is diagnosed early and managed effectively. Gynecology drugs, if timely administered, can help in reducing these deaths. It also states that 9% of women worldwide contract endometrial cancer.
Surge in prevalence of polycystic ovary syndrome is driving the gynecology drugs market revenue. As per an article published in August 2022 by Cureus, polycystic ovary syndrome (PCOS) was found in 6.8% of the participants in clinical trials.
Out of ovarian, uterine/endometrial, cervical, vulvar, and vaginal cancers, screenings are available only for cervical cancer as of now. Gynecological cancer awareness campaigns are organized worldwide in line with gynecological cancer awareness month observed every September.
The objective is to bring professionals as well as health consumers together to conduct awareness campaigns pertaining to sexual/gynecological health. Thus, increase in awareness regarding gynecological well-being is augmenting the gynecology drugs market development.
Awareness campaigns apprise about the importance of conduction of transvaginal ultrasound or routine sonography, pap smear test for cervical cancer, colposcopy, cystoscopy, curettage, hysteroscopy, and ultimately check for sexually transmitted diseases (STDs) such as chlamydia, gonorrhea, HIV, and syphilis.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest gynecology drugs market trends, North America held largest share in 2022. Rise in incidences of breast cancer, polycystic ovary syndrome, and menopausal disorders amongst women in the U.S. and Canada is fueling the market dynamics of the region.
According to the report shared by the Canadian Cancer Society in May 2022, close to 1,450 women in Canada were diagnosed with cervical cancer in 2022. Furthermore, as per the American Cancer Society’s report published in January 2022, breast cancer affects 30% of the women in the U.S.
According to the latest gynecology drugs market forecast, the industry in Asia Pacific is expected to grow at a steady pace in the near future. Rise in awareness regarding health and well-being is boosting the demand for advanced gynecological treatments, thereby driving the gynecology drugs industry share in Asia Pacific.
Key players in the global gynecology drugs industry are engaging in conducting clinical trials regarding non-hormonal therapy to treat gynecological disorders.
For instance, Bayer, in October 2021, started with a Phase III clinical development program called OASIS to evaluate the safety and efficacy of elinzanetant to treat vasomotor symptoms while battling menopause.
Allergan plc, Amgen Inc., Bayer AG, Merck & Co., Inc., Pfizer Inc., Eli Lilly Company, F. Hoffmann-La Roche Ltd., and AstraZeneca are key players in the market.
These companies have been profiled in the gynecology drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 63.4 Bn |
| Market Forecast (Value) in 2031 | US$ 96.1 Bn |
| Growth Rate (CAGR) | 4.8% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 63.4 Bn in 2022
It is projected to grow at a CAGR of 4.8% from 2023 to 2031
Growth in incidence of gynecological diseases and rise in awareness regarding gynecological wellbeing
Hospital pharmacies accounted for the largest share in 2022
North America was the dominant region in gynecology drugs market in 2022
Allergan plc, Amgen Inc., Bayer AG, Merck & Co., Inc., Pfizer Inc., Eli Lilly Company, F. Hoffmann-La Roche Ltd., and AstraZeneca
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gynecology Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gynecology Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gynecology Drugs Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapeutics, 2017-2031
6.3.1. Hormonal Therapy
6.3.1.1. Estrogen Therapy
6.3.1.2. Progestin Therapy
6.3.1.3. Combination Therapy
6.3.1.4. Thyroid Replacement Therapy
6.3.1.5. Parathyroid Hormone Therapy
6.3.1.6. Others
6.3.2. Non-hormonal Therapy
6.3.2.1. Anti-Infective Agents
6.3.2.2. Anti-neoplastic Agents
6.3.2.3. Anti-inflammatory Agents
6.3.2.4. Others
6.4. Market Attractiveness Analysis, by Therapeutics
7. Global Gynecology Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Gynecological Cancers
7.3.2. Endometriosis
7.3.3. Female Infertility
7.3.4. Menopausal Disorder
7.3.5. Gynecology Infections
7.3.6. Polycystic Ovary Syndrome
7.3.7. Contraception (Birth Control)
7.3.8. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Gynecology Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Indication
9. Global Gynecology Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Gynecology Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Therapeutics, 2017-2031
10.3.1. Hormonal Therapy
10.3.1.1. Estrogen Therapy
10.3.1.2. Progestin Therapy
10.3.1.3. Combination Therapy
10.3.1.4. Thyroid Replacement Therapy
10.3.1.5. Parathyroid Hormone Therapy
10.3.1.6. Others
10.3.2. Non-hormonal Therapy
10.3.2.1. Anti-Infective Agents
10.3.2.2. Anti-neoplastic Agents
10.3.2.3. Anti-inflammatory Agents
10.3.2.4. Others
10.4. Market Value Forecast, by Indication, 2017-2031
10.4.1. Gynecological Cancers
10.4.2. Endometriosis
10.4.3. Female Infertility
10.4.4. Menopausal Disorder
10.4.5. Gynecology Infections
10.4.6. Polycystic Ovary Syndrome
10.4.7. Contraception (Birth Control)
10.4.8. Others
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Therapeutics
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Gynecology Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Therapeutics, 2017-2031
11.3.1. Hormonal Therapy
11.3.1.1. Estrogen Therapy
11.3.1.2. Progestin Therapy
11.3.1.3. Combination Therapy
11.3.1.4. Thyroid Replacement Therapy
11.3.1.5. Parathyroid Hormone Therapy
11.3.1.6. Others
11.3.2. Non-hormonal Therapy
11.3.2.1. Anti-Infective Agents
11.3.2.2. Anti-neoplastic Agents
11.3.2.3. Anti-inflammatory Agents
11.3.2.4. Others
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Gynecological Cancers
11.4.2. Endometriosis
11.4.3. Female Infertility
11.4.4. Menopausal Disorder
11.4.5. Gynecology Infections
11.4.6. Polycystic Ovary Syndrome
11.4.7. Contraception (Birth Control)
11.4.8. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Therapeutics
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Gynecology Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Therapeutics, 2017-2031
12.3.1. Hormonal Therapy
12.3.1.1. Estrogen Therapy
12.3.1.2. Progestin Therapy
12.3.1.3. Combination Therapy
12.3.1.4. Thyroid Replacement Therapy
12.3.1.5. Parathyroid Hormone Therapy
12.3.1.6. Others
12.3.2. Non-hormonal Therapy
12.3.2.1. Anti-Infective Agents
12.3.2.2. Anti-neoplastic Agents
12.3.2.3. Anti-inflammatory Agents
12.3.2.4. Others
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Gynecological Cancers
12.4.2. Endometriosis
12.4.3. Female Infertility
12.4.4. Menopausal Disorder
12.4.5. Gynecology Infections
12.4.6. Polycystic Ovary Syndrome
12.4.7. Contraception (Birth Control)
12.4.8. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Therapeutics
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Gynecology Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Therapeutics, 2017-2031
13.3.1. Hormonal Therapy
13.3.1.1. Estrogen Therapy
13.3.1.2. Progestin Therapy
13.3.1.3. Combination Therapy
13.3.1.4. Thyroid Replacement Therapy
13.3.1.5. Parathyroid Hormone Therapy
13.3.1.6. Others
13.3.2. Non-hormonal Therapy
13.3.2.1. Anti-Infective Agents
13.3.2.2. Anti-neoplastic Agents
13.3.2.3. Anti-inflammatory Agents
13.3.2.4. Others
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1. Gynecological Cancers
13.4.2. Endometriosis
13.4.3. Female Infertility
13.4.4. Menopausal Disorder
13.4.5. Gynecology Infections
13.4.6. Polycystic Ovary Syndrome
13.4.7. Contraception (Birth Control)
13.4.8. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Therapeutics
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Gynecology Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Therapeutics, 2017-2031
14.3.1. Hormonal Therapy
14.3.1.1. Estrogen Therapy
14.3.1.2. Progestin Therapy
14.3.1.3. Combination Therapy
14.3.1.4. Thyroid Replacement Therapy
14.3.1.5. Parathyroid Hormone Therapy
14.3.1.6. Others
14.3.2. Non-hormonal Therapy
14.3.2.1. Anti-Infective Agents
14.3.2.2. Anti-neoplastic Agents
14.3.2.3. Anti-inflammatory Agents
14.3.2.4. Others
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Gynecological Cancers
14.4.2. Endometriosis
14.4.3. Female Infertility
14.4.4. Menopausal Disorder
14.4.5. Gynecology Infections
14.4.6. Polycystic Ovary Syndrome
14.4.7. Contraception (Birth Control)
14.4.8. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Therapeutics
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Allergan plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Amgen Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Bayer AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Pfizer Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Eli Lilly Company
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. AstraZeneca
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
List of Tables
Table 01: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 02: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 03: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 07: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 08: North America Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 11: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 12: Europe Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 15: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 16: Asia Pacific Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 19: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Latin America Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 23: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 24: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Gynecology Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Gynecology Drugs Market Revenue (US$ Mn), by Therapeutics, 2022
Figure 03: Global Gynecology Drugs Market Value Share, by Therapeutics, 2022
Figure 04: Global Gynecology Drugs Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Gynecology Drugs Market Value Share, by Indication, 2022
Figure 06: Global Gynecology Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2022
Figure 08: Global Gynecology Drugs Market Value Share, by Region, 2022
Figure 09: Global Gynecology Drugs Market Value (US$ Mn) Forecast, 2023-2031
Figure 10: Global Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 11: Global Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 12: Global Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 13: Global Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 14: Global Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Gynecology Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Gynecology Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Gynecology Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 20: North America Gynecology Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 22: North America Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 23: North America Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 25: North America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 26: North America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 28: Europe Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 29: Europe Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 31: Europe Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 32: Europe Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 34: Europe Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 35: Europe Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 36: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 37: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 40: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 41: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 43: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 44: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 45: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 46: Latin America Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 47: Latin America Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 49: Latin America Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 50: Latin America Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Latin America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 52: Latin America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 53: Latin America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 54: Middle East & Africa Gynecology Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 55: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 58: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 59: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 61: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 62: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gynecology Drugs Market